C反应蛋白–甘油三酯–葡萄糖指数与帕金森病相关性的加权横断面研究:基于NHANES数据库的分析
Association between the C-Reactive Protein-Triglyceride-Glucose Index and Parkinsonism: A Weighted Cross-Sectional Study Based on the NHANES Database
DOI: 10.12677/acm.2026.1682923, PDF,   
作者: 范梦露:安徽医科大学第一附属医院神经内科,安徽 合肥;阜阳市妇女儿童医院老年医学科,安徽 阜阳;张超辉:阜阳市妇女儿童医院小儿外科,安徽 阜阳;孙中武*:安徽医科大学第一附属医院神经内科,安徽 合肥
关键词: C反应蛋白–甘油三酯–葡萄糖指数;帕金森病;NHANES;胰岛素抵抗;慢性炎症;C-Reactive Protein-Triglyceride-Glucose Index; Parkinsonism; NHANES; Insulin Resistance; Chronic Inflammation
摘要: 目的:探讨C反应蛋白–甘油三酯–葡萄糖指数(CTI)与帕金森病(PD)之间的关联。方法:基于NHANES数据库,纳入12,291名参与者并进行复杂抽样加权分析。将CTI分别作为连续变量和三分位分组变量纳入加权Logistic回归模型,采用限制性立方样条(RCS)评估剂量–反应关系,同时采用ROC曲线比较CTI、TyG和CRP对PD的区分效能。结果:纳入样本加权后代表1,033,961,743名人群,PD加权患病率为1.15%。随着CTI三分位升高,PD加权患病率由T1组0.72%升至T3组1.71%。在完全调整模型中,CTI作为连续变量时与PD患病可能性升高相关(OR = 1.79, 95% CI: 1.23~2.60, P = 0.003);与T1 (5.2~8.01)组相比,T3 (8.81~13.11)组PD患病可能性较高(OR = 2.00, 95% CI, 1.01~4.00, P = 0.049),趋势检验P = 0.003。RCS分析提示CTI与PD之间呈正向线性关联(非线性检验P = 0.118)。ROC分析显示,CTI、TyG和CRP区分PD的AUC分别为0.636、0.558和0.574。亚组分析显示总体关联稳定(OR = 1.87, 95% CI: 1.41~2.50, P < 0.001),年龄分层存在交互作用(交互作用检验P = 0.003)。结论:在NHANES加权人群中,较高CTI与PD患病可能性升高相关,与TyG和CRP相比,CTI对PD具有相对更好的区分效能。
Abstract: Objective: To investigate the association between the C-reactive protein-triglyceride-glucose index (CTI) and Parkinsonism (PD). Methods: Based on the NHANES database, 12,291 participants were included and analyzed using complex sampling weights. CTI was included in weighted logistic regression models both as a continuous variable and as a tertile-based categorical variable. Restricted cubic spline (RCS) analysis was used to evaluate the dose-response relationship. Receiver operating characteristic (ROC) curves were used to compare the discriminatory performance of CTI, TyG, and CRP for PD. Results: The weighted sample represented 1,033,961,743 individuals, and the weighted prevalence of PD was 1.15%. With increasing CTI tertiles, the weighted prevalence of PD increased from 0.72% in T1 to 1.71% in T3. In the fully adjusted model, CTI as a continuous variable was associated with increased odds of PD (OR = 1.79, 95% CI: 1.23~2.60, P = 0.003). Compared with the T1 group (5.2~8.01), the T3 group (8.81~13.11) had higher odds of PD (OR = 2.00, 95% CI: 1.01~4.00, P = 0.049), with a P value for trend of 0.003. RCS analysis suggested a positive linear association between CTI and PD (P for nonlinearity = 0.118). ROC analysis showed that the AUC values of CTI, TyG, and CRP for discriminating PD were 0.636, 0.558, and 0.574, respectively. Subgroup analysis showed a stable overall association (OR = 1.87, 95% CI: 1.41~2.50, P < 0.001), with an interaction by age stratification (P for interaction = 0.003). Conclusion: In the weighted NHANES population, higher CTI was associated with increased odds of Parkinsonism. Compared with TyG and CRP, CTI showed relatively better discriminatory performance for PD.
文章引用:范梦露, 张超辉, 孙中武. C反应蛋白–甘油三酯–葡萄糖指数与帕金森病相关性的加权横断面研究:基于NHANES数据库的分析[J]. 临床医学进展, 2026, 16(8): 1459-1468. https://doi.org/10.12677/acm.2026.1682923

参考文献

[1] Poewe, W., Seppi, K., Tanner, C.M., Halliday, G.M., Brundin, P., Volkmann, J., et al. (2017) Parkinson Disease. Nature Reviews Disease Primers, 3, Article No. 17013.
https://doi.org/10.1038/nrdp.2017.13
[2] Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S.G., Croteau, D.L., et al. (2019) Ageing as a Risk Factor for Neurodegenerative Disease. Nature Reviews Neurology, 15, 565-581.
https://doi.org/10.1038/s41582-019-0244-7
[3] Athauda, D. and Foltynie, T. (2016) Insulin Resistance and Parkinson’s Disease: A New Target for Disease Modification? Progress in Neurobiology, 145, 98-120.
https://doi.org/10.1016/j.pneurobio.2016.10.001
[4] Xu, T., Dong, W., Liu, J., Yin, P., Wang, Z., Zhang, L., et al. (2024) Disease Burden of Parkinson’s Disease in China and Its Provinces from 1990 to 2021: Findings from the Global Burden of Disease Study 2021. The Lancet Regional Health—Western Pacific, 46, Article 101078.
https://doi.org/10.1016/j.lanwpc.2024.101078
[5] Hogg, E., Athreya, K., Basile, C., Tan, E.E., Kaminski, J. and Tagliati, M. (2018) High Prevalence of Undiagnosed Insulin Resistance in Non-Diabetic Subjects with Parkinson’s Disease. Journal of Parkinson’s Disease, 8, 259-265.
https://doi.org/10.3233/jpd-181305
[6] Chang, Y., Park, J., Yun, J.Y. and Song, T.J. (2025) The Association between the Triglyceride-Glucose Index and the Incidence Risk of Parkinson’s Disease: A Nationwide Cohort Study. Journal of Movement Disorders, 18, 138-148.
https://doi.org/10.14802/jmd.24131
[7] Cheng, Y., You, S., Wang, X., Ge, Y., Li, L., Ren, T., et al. (2025) A High Triglyceride-Glucose Index Correlates with Cognitive Impairment in Parkinson’s Disease: A Cross-Sectional Study. Frontiers in Neuroscience, 19, Article 1620118.
https://doi.org/10.3389/fnins.2025.1620118
[8] Cao, H., Zhao, Y., Chen, Z., Zou, X., Du, X., Yi, L., et al. (2025) Triglyceride-Glucose Index Predicts Cognitive Decline and Striatal Dopamine Deficiency in Parkinson Disease in Two Cohorts. npj Parkinson’s Disease, 11, Article No. 240.
https://doi.org/10.1038/s41531-025-01100-1
[9] Qiu, X., Xiao, Y., Wu, J., Gan, L., Huang, Y. and Wang, J. (2019) C-Reactive Protein and Risk of Parkinson’s Disease: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 10, Article 384.
https://doi.org/10.3389/fneur.2019.00384
[10] Sawada, H., Oeda, T., Umemura, A., Tomita, S., Kohsaka, M., Park, K., et al. (2015) Baseline C-Reactive Protein Levels and Life Prognosis in Parkinson Disease. PLOS ONE, 10, e0134118.
https://doi.org/10.1371/journal.pone.0134118
[11] Yue, C., Wang, X., Li, Y., Yuan, S., Wang, Z., Liu, H., et al. (2026) Association of the C-Reactive Protein-Triglyceride-Glucose (CTI) Index and Its Central Obesity-Modified Derivatives with Incident Cardiometabolic Multimorbidity: Results from Two Prospective Cohorts in China and England. Cardiovascular Diabetology, 1-45.
https://doi.org/10.1186/s12933-026-03238-5
[12] Liao, C., Liu, L., Bao, W., Lai, H., Tian, R., Zhang, S., et al. (2026) Joint Associations of Anthropometric Indices and C-Reactive Protein-Triglyceride-Glucose Index with Incident Hypertension: A Stratified Analysis by Blood Pressure Level from the CHARLS, 2011-2020. Cardiovascular Diabetology, 25, Article No. 135.
https://doi.org/10.1186/s12933-026-03132-0
[13] Tang, S., Wang, H., Li, K., Chen, Y., Zheng, Q., Meng, J., et al. (2024) C-Reactive Protein-Triglyceride Glucose Index Predicts Stroke Incidence in a Hypertensive Population: A National Cohort Study. Diabetology & Metabolic Syndrome, 16, Article No. 277.
https://doi.org/10.1186/s13098-024-01529-z
[14] Li, H., Chen, L., Wang, M., Cheng, W., Du, Z. and Huang, Y. (2026) Associations of C-Reactive Protein, Triglyceride-Glucose Index, and the C-Reactive Protein-Triglyceride Glucose Index with Multistate Trajectories in the Cardiovascular-Renal-Diabetes Cluster. Frontiers in Endocrinology, 17, Article 1758467.
https://doi.org/10.3389/fendo.2026.1758467
[15] Ke, L., Zhao, L., Xing, W. and Tang, Q. (2024) Association between Parkinson’s Disease and Cardiovascular Disease Mortality: A Prospective Population-Based Study from NHANES. Lipids in Health and Disease, 23, Article No. 212.
https://doi.org/10.1186/s12944-024-02200-2
[16] Zhou, X., Zhao, J., Liu, Y., Sun, X., Li, X., Ren, J., et al. (2024) Association between Serum Potassium and Parkinson’s Disease in the US (NHANES 2005-2020). Frontiers in Neuroscience, 18, Article 1387266.
https://doi.org/10.3389/fnins.2024.1387266
[17] Huang, F., Hao, J., Chen, C., Liu, Q. and He, D. (2025) Reduced Composite Dietary Antioxidant Index Increases the Risk of Parkinson’s Disease and All-Cause Mortality in Parkinson’s Disease Patients: Evidence from the NHANES Database. Frontiers in Aging Neuroscience, 17, Article 1510654.
https://doi.org/10.3389/fnagi.2025.1510654
[18] Ruan, G.T., Xie, H.L., Zhang, H.Y., et al. (2022) A Novel Inflammation and Insulin Resistance Related Indicator to Predict the Survival of Patients with Cancer. Frontiers in Endocrinology, 13, Article 905266.
https://doi.org/10.3389/fendo.2022.905266
[19] Fiory, F., Perruolo, G., Cimmino, I., Cabaro, S., Pignalosa, F.C., Miele, C., et al. (2019) The Relevance of Insulin Action in the Dopaminergic System. Frontiers in Neuroscience, 13, Article 868.
https://doi.org/10.3389/fnins.2019.00868
[20] Lee, J.K., Tran, T. and Tansey, M.G. (2009) Neuroinflammation in Parkinson’s Disease. Journal of Neuroimmune Pharmacology, 4, 419-429.
https://doi.org/10.1007/s11481-009-9176-0
[21] Isik, S., Yeman Kiyak, B., Akbayir, R., Seyhali, R. and Arpaci, T. (2023) Microglia Mediated Neuroinflammation in Parkinson’s Disease. Cells, 12, Article 1012.
https://doi.org/10.3390/cells12071012
[22] Reeve, A., Simcox, E. and Turnbull, D. (2014) Ageing and Parkinson’s Disease: Why Is Advancing Age the Biggest Risk Factor? Ageing Research Reviews, 14, 19-30.
https://doi.org/10.1016/j.arr.2014.01.004
[23] Calabrese, V., Santoro, A., Monti, D., Crupi, R., Di Paola, R., Latteri, S., et al. (2018) Aging and Parkinson’s Disease: Inflammaging, Neuroinflammation and Biological Remodeling as Key Factors in Pathogenesis. Free Radical Biology and Medicine, 115, 80-91.
https://doi.org/10.1016/j.freeradbiomed.2017.10.379
[24] Tenison, E. and Henderson, E.J. (2020) Multimorbidity and Frailty: Tackling Complexity in Parkinson’s Disease. Journal of Parkinson’s Disease, 10, S85-S91.
https://doi.org/10.3233/jpd-202105
[25] Han, M.N., Finkelstein, D.I., McQuade, R.M. and Diwakarla, S. (2022) Gastrointestinal Dysfunction in Parkinson’s Disease: Current and Potential Therapeutics. Journal of Personalized Medicine, 12, Article 144.
https://doi.org/10.3390/jpm12020144
[26] Ma, K., Xiong, N., Shen, Y., Han, C., Liu, L., Zhang, G., et al. (2018) Weight Loss and Malnutrition in Patients with Parkinson’s Disease: Current Knowledge and Future Prospects. Frontiers in Aging Neuroscience, 10, Article 1.
https://doi.org/10.3389/fnagi.2018.00001